Onco Actu du 20 juin 2018

	1.1 Biologie - Gènes
New human gene tally reignites debate [Nature] Some fifteen years after the human genome was sequenced, researchers still can’t agree on how many genes it contains.
	2.10 Etiologie - Alcool
The association of lifetime alcohol use with mortality and cancer risk in older adults: A cohort study [PLoS Medicine] The study supports a J-shaped association between alcohol and mortality in older adults, which remains after adjustment for cancer risk. The results indicate that intakes below 1 drink per day were associated with the lowest risk of death.
What drinking alcohol means for your cancer and death risk [CNN] "The reasons for the reduced risk in light drinkers compared to never drinkers are still open to debate amongst the scientific community. Some have suggested that alcohol may have cardio-protective effects that may reduce risk of cardiovascular disease."
	4. Dépistage, diagnostic et pronostic
Benjamin Mazer: Theranos’ dystopian vision lives on [BMJ Blogs] Plenty of real companies are still carrying the “early detection” baton. Techno-optimism and bio-naiveté still mix within Silicon Valley’s veins, even as doctors are taking the problem of overdiagnosis more seriously.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
News outlets focus on one dramatic outcome. But did researchers omit data from hundreds in clinical trial? [HealthNewsReview] “So this one amazing outcome is picked out of dozens or hundreds cases in the trial … we have no way of knowing. Yet in the reporting form to the journal — which is designed by them to address increasing problems with transparency and reproducibility — the authors identify this as a ‘single case report’ and that ‘no data was excluded’. How can that be? Is the denominator 1 or is it the 332 people enrolled in the trial?”
	5.12.5 Immunothérapies - Pharma
I/O player iTeos lines up a $75M round as it preps for human studies, plans a leap to US hub [EndPoints] The group has hauled in a $75 million round designed to get its lead drug — an adenosine A2A antagonist — into the clinic later this year.
	5.12.6 Immunothérapies - AMM
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label [Amgen] BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy.
	5.2 Pharma
Latecomer Sanofi looks to catch next wave of cancer therapies [Reuters] Sanofi’s main business areas include drugs for diabetes, heart diseases and vaccines, with cancer treatments making up only about 4 percent of sales. Its cancer drug sales totaled $1.7 billion last year, compared with Roche’s $25.9 billion.
	5.2.2 Pharma - Fusions & Acquisitions
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine [Xconomy] Foundation has lost money for years trying to boost the commercial uptake of these tests, which have struggled to gain traction with payers and community oncologists. But in the past year the company has made important strides, at least with regulators.
	6.1 Observation
Survival rate for most common type of pancreatic cancer is half as good as previously thought [The Telegraph] A three year study by the London School of Hygiene and Tropical Medicine on behalf of Pancreatic Cancer UK found that the true figures have been masked because they are published collectively with another type called pancreatic neuroendocrine tumours or PNET, which has a far higher survival rate.
	6.3 Associations/Fondations
What Do Foundations Have In Mind With The Phrase “Social Determinants of Health”? [Health Affairs] Any foundation interested in pursuing an SDOH strategy would be advised to engage its board and staff in an exploration of the different SDOH paradigms we observed in our sample—social determinants of population health, social determinants of health disparities, and a broad definition of health.
	6.6 Publications
How will you judge me if not by impact factor? [Nature] Stop saying that publication metrics don’t matter, and tell early-career researchers what does, says John Tregoning.